Smith, C.J., McKay, G.A. and Fisher, M. (2008) Diabetes, colorectal cancer and cyclooxygenase 2 inhibition. International Journal of Clinical Practice, 62(5), pp. 810-815. (doi: 10.1111/j.1742-1241.2008.01726.x) (PMID:18373616)
Full text not currently available from Enlighten.
Abstract
Diabetes is a risk factor for cancer and specifically colorectal cancer. It is also associated with increased cancer mortality. Aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase 2 (Cox-2) inhibitors have been shown to decrease the incidence of colorectal cancer. This effect may be mediated by inhibiting prostaglandin synthesis. Long-term use of high-dose aspirin and NSAIDs is associated with significant gastrointestinal side effects. Unfortunately, the use of Cox-2 inhibitors is associated with an increased incidence of acute myocardial infarction and death from cardiovascular disease. The increased risk of cardiovascular disease in patients with diabetes results in the loss of the potential to use Cox-2 inhibitors for cancer chemoprophylaxis. Until a safer type of Cox-2 inhibitor is available, or low-dose aspirin is evaluated for chemoprophylaxis, a more intense screening programme for colorectal cancer may be appropriate for patients with diabetes, especially men. Healthcare professionals managing patients with diabetes should be aware of the increased risk of this type of cancer.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | McKay, Dr Gerard |
| Authors: | Smith, C.J., McKay, G.A., and Fisher, M. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
| Journal Name: | International Journal of Clinical Practice |
| Publisher: | Wiley-Blackwell Publishing Ltd. |
| ISSN: | 1368-5031 |
| ISSN (Online): | 1742-1241 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details